◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › F › FENC

Fennec Pharmaceuticals Inc (FENC) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-03

Fennec Pharmaceuticals Inc (FENC) operates in the BIOTECHNOLOGY industry and is headquartered in Research Triangle Park, United States with about 35 employees. Its market capitalization is roughly $359 million. In the fiscal year ended 2025-12-31, FENC reported $45M in revenue and ($10M) in net income.

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.

Interactive charts & full statements → Open the FENC valuation workbench →

FENC Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$59M	$45M	$48M	$21M	$2M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—
Gross Profit	$56M	$41M	$44M	$20M	$1M	$0M	$0M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—
Gross Margin %	94.9%	91.6%	93.3%	94.1%	94.4%	0.0%	100.0%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($1M)	($6M)	$2M	($13M)	($23M)	($17M)	($18M)	($13M)	($10M)	($7M)	($3M)	($2M)	($3M)	($2M)	($4M)	($3M)	($5M)	($3M)	($14M)	($14M)	($19M)
Operating Margin %	-1.7%	-14.2%	5.2%	-61.4%	-1481.3%	-10131.2%	-10520.6%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income	($4M)	($10M)	$0M	($16M)	($24M)	($17M)	($18M)	($12M)	($10M)	($7M)	($3M)	($1M)	($2M)	$2M	($5M)	$5M	($8M)	($3M)	($14M)	($13M)	($19M)
Net Margin %	-6.8%	-21.8%	-0.9%	-75.5%	-1544.9%	-10203.5%	-10652.4%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA	($2M)	($7M)	$5M	($12M)	($23M)	($17M)	($18M)	($13M)	$1M	$0M	$0M	($1M)	($2M)	$2M	($5M)	$5M	($5M)	($3M)	($14M)	($14M)	($18M)
Earnings Per Share (EPS)	$-0.11	$-0.34	$-0.02	$-0.60	$-0.90	$-0.67	$-0.76	$-0.63	$-0.52	$-0.47	$-0.22	$-0.09	$-0.22	$0.17	$-0.62	$0.58	$-1.11	$-0.98	$-4.43	$-4.78	$-12.89
Shares Outstanding (M)	36M	29M	27M	27M	26M	26M	24M	20M	19M	15M	13M	11M	10M	11M	8M	8M	7M	3M	3M	3M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FENC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$18M	$15M	$14M	$12M	$10M	$9M	$8M	$7M
Gross Profit	$17M	$15M	$12M	$12M	$9M	$8M	$7M	$6M
Gross Margin %	96.0%	96.2%	87.2%	94.7%	90.0%	95.7%	91.6%	80.5%
Operating Income (EBIT)	$2M	$0M	($3M)	$0M	($3M)	($1M)	($1M)	($5M)
Operating Margin %	9.7%	-0.8%	-18.7%	-1.6%	-28.3%	-9.4%	-12.1%	-74.9%
Net Income	$2M	$0M	($5M)	($1M)	($3M)	($1M)	($2M)	($6M)
Net Margin %	11.0%	1.3%	-34.8%	-5.1%	-32.7%	-13.3%	-25.1%	-82.2%
EBITDA	$2M	$0M	($4M)	$0M	($3M)	($1M)	($1M)	($5M)
Earnings Per Share (EPS)	$0.05	$0.01	$-0.15	$-0.02	$-0.11	$-0.04	$-0.07	$-0.21
Shares Outstanding (M)	36M	36M	31M	28M	28M	28M	27M	27M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FENC Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($3M)	($12M)	$27M	($17M)	($18M)	($14M)	($16M)	($9M)	($8M)	($4M)	($2M)	($2M)	($2M)	($2M)	($3M)	($3M)	($2M)	($5M)	($11M)	($13M)	($13M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($3M)	($12M)	$27M	($17M)	($18M)	($14M)	($16M)	($9M)	($8M)	($4M)	($2M)	($2M)	($2M)	($2M)	($3M)	($5M)	($2M)	($5M)	($11M)	($13M)	($13M)
FCF Margin %	-5.1%	-27.9%	56.8%	-80.7%	-1176.4%	-8365.9%	-9173.5%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dividends Paid	—	—	—	—	$1M	—	—	—	—	$0M	$0M	$0M	$0M	$0M	—	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FENC Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$0M	$2M	($6M)	$1M	($4M)	($4M)	($1M)	($2M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$0M	$2M	($6M)	$1M	($4M)	($4M)	($1M)	($2M)
FCF Margin %	0.3%	15.8%	-43.3%	12.0%	-38.2%	-49.3%	-18.6%	-31.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

FENC Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$76M	$70M	$45M	$27M	$27M	$22M	$31M	$14M	$23M	$28M	$4M	$1M	$2M	$2M	$2M	$5M	$6M	$1M	$6M	$17M	$17M
Cash & Cash Equivalents	$41M	$37M	$27M	$13M	$24M	$21M	$30M	$14M	$23M	$28M	$4M	$1M	$2M	$2M	$2M	$5M	$6M	$1M	$5M	$16M	$6M
Total Liabilities	$33M	$35M	$51M	$38M	$30M	$7M	$2M	$2M	$2M	$2M	$0M	$0M	$2M	$3M	$7M	$5M	$11M	$0M	$3M	$3M	$9M
Total Debt (Short + Long-Term)	$0M	$0M	$19M	$31M	$25M	$5M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$3M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$42M	$35M	($6M)	($12M)	($3M)	$16M	$29M	$12M	$21M	$27M	$4M	$1M	$1M	($1M)	($5M)	$0M	($5M)	$0M	$3M	$14M	$8M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FENC viewer.

Other Companies in BIOTECHNOLOGY

MPLT · MapLight Therapeutics, Inc. Common Stock — $378 million
AUTL · Autolus Therapeutics Ltd — $377 million
AGMB · AgomAb Therapeutics NV American Depositary Shares — $369 million
CTNM · Contineum Therapeutics, Inc. Class A Common Stock — $365 million
KYTX · Kyverna Therapeutics, Inc. Common Stock — $351 million
SPRY · ARS Pharmaceuticals, Inc — $336 million
AVIR · Atea Pharmaceuticals Inc — $330 million
ARCT · Arcturus Therapeutics Holdings Inc — $314 million

← FEMY All “F” companies FENG →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.